专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005007090A2 INHIBITORS OF THE MAP KINASE PATHWAY 审中-公开
标题翻译： MAP激活途径的抑制剂
公开(公告)号：WO2005007090A2
公开(公告)日：2005-01-27
申请号：PCT/US2004/021514
申请日：2004-07-02
申请人： PRESIDENT AND FELLOWS OF HARVARD COLLEGE , BLENIS, John , MURPHY, Leon, O.
发明人： BLENIS, John , MURPHY, Leon, O.
IPC分类号： A61K
CPC分类号： G01N33/5011 , A61K47/62 , G01N33/5041 , G01N33/57496 , G01N33/6893 , G01N2333/91205 , G01N2500/02
摘要： MAP kinases (e.g., ERKI/2) phosphorylate a variety of target proteins including, for example, several immediate early gene products (e.g., Fos, Myc, and Jun family proteins). Certain phosphorylation reactions require binding of the MAP kinase to the DEF domain of the target protein. Inhibitors that block this interaction may be useful therapeutics for human disease, including as antineoplastic agents. Also disclosed are screening assays useful for identifying compounds that inhibit the MAP kinase-DEF domain interaction.
摘要翻译： MAP激酶（例如，ERKI / 2）磷酸化各种靶蛋白，包括例如若干立即早期基因产物（例如Fos，Myc和Jun家族蛋白）。某些磷酸化反应需要MAP激酶与靶蛋白的DEF结构域的结合。阻断这种相互作用的抑制剂可能是人类疾病的有用治疗剂，包括作为抗肿瘤剂。还公开了用于鉴定抑制MAP激酶-DF结构域相互作用的化合物的筛选测定法。

2. 发明申请

WO2004024084A2 RB PAHTWAY AND CHROMATIN REMODELING GENES THAT ANTAGONIZE LET-60 RAS SIGNALING 审中-公开
标题翻译： RB PAHTWAY和铬铁蛋白重塑基因，阻止LET-60 RAS信号传导
公开(公告)号：WO2004024084A2
公开(公告)日：2004-03-25
申请号：PCT/US2003/028626
申请日：2003-09-12
申请人： MASSACHUSETTS INSTITUTE OF TECHNOLOGY , HORVITZ, H., Robert, Ph., D. , CEOL, Craig , ANDERSEN, Erik
发明人： HORVITZ, H., Robert, Ph., D. , CEOL, Craig , ANDERSEN, Erik
IPC分类号： A61K
CPC分类号： C07K14/47
摘要： In general, the invention provides methods and compositions useful in the treatment of a neoplasia. These compositions include new components of the Rb pathway that function in chromatin remodeling and antagonize Ras signaling.
摘要翻译：通常，本发明提供可用于治疗瘤形成的方法和组合物。这些组合物包括Rb途径的新组分，其在染色质重塑中发挥功能并拮抗Ras信号。

3. 发明申请

WO2006034507A3 METHODS OF DIAGNOSING AND TREATING COMPLICATIONS OF PREGNANCY 审中-公开
公开(公告)号：WO2006034507A3
公开(公告)日：2006-03-30
申请号：PCT/US2005/034483
申请日：2005-09-26
申请人： BETH ISRAEL - DEACONESS MEDICAL CENTER , KARUMANCHI, S., Ananth , SUKHATME, Vikas
发明人： KARUMANCHI, S., Ananth , SUKHATME, Vikas
IPC分类号： G01N33/53 , A61K39/395 , C07H21/04 , C12N5/06
摘要： Disclosed herein are methods for diagnosing a pregnancy related hypertensive disorder or a propensity to develop a pregnancy related hypertensive disorder by measuring the level or biological activity of soluble endoglin. Also disclosed herein are methods for treating a a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using compounds that alter soluble endoglin levels or biological activity.

4. 发明申请

WO2006028508A2 METHODS AND APPARATUS FOR CHARACTERIZING POLYNUCLEOTIDES 审中-公开
标题翻译：用于表征多核苷酸的方法和装置
公开(公告)号：WO2006028508A2
公开(公告)日：2006-03-16
申请号：PCT/US2005/009702
申请日：2005-03-23
申请人： PRESIDENT AND FELLOWS OF HARVARD COLLEGE , REGENTS OF THE UNIVERSITY OF CALIFORNIA , AGILENT TECHNOLOGIES, INC. , AKESON, Mark , BRANTON, Daniel , DEAMER, David, W. , SAMPSON, Jeffrey, R.
发明人： AKESON, Mark , BRANTON, Daniel , DEAMER, David, W. , SAMPSON, Jeffrey, R.
IPC分类号： C12Q1/68
CPC分类号： G01N33/48721 , B01L3/502707 , B01L3/502761 , B01L2300/0896 , B01L2400/0475 , B82Y5/00 , B82Y30/00 , C12Q1/6869 , C12Q2565/631 , C12Q2521/543
摘要： Systems and methods for analysis of polymers, e.g., polynucleotides, are provided. The systems are capable of analyzing a polymer at a specified rate. One such analysis system includes a structure having a nanopore aperture and a molecular motor, e.g., a polymerase, adjacent the nanopore aperture.
摘要翻译：提供了用于分析聚合物的系统和方法，例如多核苷酸。该系统能够以指定的速率分析聚合物。一个这样的分析系统包括具有纳米孔孔的结构和邻近纳米孔孔的分子马达，例如聚合酶。

5. 发明申请

WO2005039502A2 MACROMER-MELT FORMULATIONS 审中-公开
标题翻译：大豆熔融配方
公开(公告)号：WO2005039502A2
公开(公告)日：2005-05-06
申请号：PCT/US2004/035346
申请日：2004-10-22
申请人： AZOPAX THERAPEUTICS LLC , ROWE, Stephen, C. , ANANVAJJULA, Durga
发明人： ROWE, Stephen, C. , ANANVAJJULA, Durga
IPC分类号： A61K
CPC分类号： A61K31/74 , A61K9/0019 , A61K9/0075 , A61K9/1641 , A61K9/1694 , C08F290/00 , C08L53/00 , C08L2666/02
摘要： The invention provides methods and articles for the administration of a biologically active substance (BAS). These methods and articles provide for the controlled and sustained delivery of relatively large quantities of these substances with a low burst effect. The articles made using the method of the invention have increased percentages (w/w) of macromer, increased crosslinking density, and reduced pore size in comparison to articles made using solution methods.
摘要翻译：本发明提供了用于施用生物活性物质（BAS）的方法和物品。这些方法和制品提供了控制和持续输送相对大量的这些物质的低爆裂效应。与使用溶液法制备的制品相比，使用本发明的方法制得的制品具有提高的大分子单体百分比（w / w），增加的交联密度和减小的孔径。

6. 发明申请

WO2005034881A2 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS INVOLVING ABNORMAL ANGIOGENESIS 审中-公开
标题翻译：治疗涉及异常血管发生的病症的方法和组合物
公开(公告)号：WO2005034881A2
公开(公告)日：2005-04-21
申请号：PCT/US2004/033735
申请日：2004-10-12
申请人： BETH ISRAEL DEACONESS MEDICAL CENTER , SHIE, Jue-Lon , LI, Jian , LAHAM, Roger, J.
发明人： SHIE, Jue-Lon , LI, Jian , LAHAM, Roger, J.
IPC分类号： A61K
CPC分类号： C07K14/4705 , A61K38/1709 , G01N33/74 , G01N2333/515 , G01N2500/04 , Y10T436/143333
摘要： The present invention features methods and compositions for preventing, reducing, or treating hypoxia and,pathological disorders involving abnormal angiogenesis. Thus, the present invention is useful for treating, reducing, or preventing ischernic conditions (characterized by a reduced blood flow or reduced angiogenesis, e.g., a myocardial infarct) and hypervascular conditions (characterized by excessive angiogenesis, e.g., cancer). Where an increase in angiogenesis is desired, the mammal being treated for an ischernic condition is provided with Related Transcriptional Enhancer Factor-1 (RTEF-1; as a recombinant polypeptide or as an expression vector) sufficient to increase expression of VEGF, FGFR, or COX-2. This results in a concomitant increase in angiogenesis. Conversely, a mammal being treated for a hypervascular condition is administered a composition that reduces the levels of RTEF-1, thereby reducing the expression of VEGF, FGFR, or COX-2, which results in a decrease in angiogenesis. Also disclosed are screening methods that make use of RTEF-1 for the identification of novel therapeutics for the treatment, prevention, or reduction of pathological disorders involving hypoxia or abnormal angiogenesis, namely, ischernic or hypervascular conditions.
摘要翻译：本发明的特征在于用于预防，减少或治疗缺氧和涉及异常血管生成的病理学病症的方法和组合物。因此，本发明可用于治疗，减轻或预防血液循环状况（以血流量减少或血管生成减少，例如心肌梗塞为特征）和血管过度状况（以过度血管生成如癌症为特征）。当需要增加血管生成时，为肌肉病症治疗的哺乳动物提供足以增加VEGF，FGFR或VEGF的表达的相关转录增强因子-1（RTEF-1;作为重组多肽或表达载体） COX-2。这导致血管生成的伴随增加。相反地，正在治疗血管过多病症的哺乳动物施用降低RTEF-1水平的组合物，由此降低VEGF，FGFR或COX-2的表达，这导致血管生成的降低。还公开了使用RTEF-1来筛选用于治疗，预防或减少涉及缺氧或异常血管生成的病理学病症（即，ischernic或hypervascular病症）的新型治疗剂的筛选方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式